[
  {
    "ts": null,
    "headline": "Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis",
    "summary": "WILMINGTON, Del., June 20, 2025--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis",
    "url": "https://finnhub.io/api/news?id=25dc6b70e8f74a99fb319e4e3893882b3922b2b2c2bb9bc42e5a8c8711f8cee2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750451400,
      "headline": "Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis",
      "id": 135446312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., June 20, 2025--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis",
      "url": "https://finnhub.io/api/news?id=25dc6b70e8f74a99fb319e4e3893882b3922b2b2c2bb9bc42e5a8c8711f8cee2"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for […]",
    "url": "https://finnhub.io/api/news?id=3bf587b6a134a11021044902dd3648f50d5df8c7f4a2b885559963dea701049b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750450037,
      "headline": "Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions",
      "id": 135445747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for […]",
      "url": "https://finnhub.io/api/news?id=3bf587b6a134a11021044902dd3648f50d5df8c7f4a2b885559963dea701049b"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Says FDA Extended Review Period for Opzelura",
    "summary": "By Dean Seal Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11. The...",
    "url": "https://finnhub.io/api/news?id=0314e438ab0b86cbda00b907b33555725d9ecf6d535165e81e5c3679e5678699",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750440368,
      "headline": "Incyte Says FDA Extended Review Period for Opzelura",
      "id": 135444216,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "By Dean Seal Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11. The...",
      "url": "https://finnhub.io/api/news?id=0314e438ab0b86cbda00b907b33555725d9ecf6d535165e81e5c3679e5678699"
    }
  }
]